[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535835":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":44,"locations":52,"responsibleParty":66,"collaborators":68,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":26,"enrollmentInfo":91,"targetDuration":26,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":26,"overallStatus":54,"whyStopped":26,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patiromer","EXPERIMENTAL","All participants will receive patiromer 8.4g\u002Fd (powder for oral suspension) during one of the two 12-week study periods. Following a 6-week washout, participants will switch from the patiromer arm to the placebo arm or vice versa (cross-over design).",[13],"Drug: Patiromer 8400 MG [Veltassa]",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","All participants will receive placebo 8.4g\u002Fd (powder for oral suspension) during one of the two 12-week study periods. Following a 6-week washout, participants will switch from the patiromer arm to the placebo arm or vice versa (cross-over design).",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Patiromer 8400 MG [Veltassa]","Patiromer is a cation-exchanging polymer intended for oral intake that is not resorbed from the gastro-intestinal tract. Patiromer has been approved by the European Medicines Agency (EMA) and is available for clinical use in The Netherlands for the indication of hyperkalemia in adults. It contains calcium-sorbitol complex as a counter-ion. Patiromer increases the faecal excretion of potassium in the gastro-intestinal lumen by exchange with part of the calcium. This results in a lower concentration of free potassium in the gastro-intestinal lumen, reducing in turn plasma potassium concentration. After initiation of patiromer, a clinically significant reduction in plasma potassium can be observed at around 7 hours, the effect persists for approximately 24 hours. Patiromer is excreted by the fecal route, 24-48 hrs after ingestion. Since patiromer is not absorbed or metabolized by the body, other drugs are not expected to influence the efficacy of patiromer.",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.",[15],[31,35,38,41],{"name":32,"affiliation":33,"role":34},"Liffert Vogt, prof. dr.","Amsterdam University Medical Centre","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Aaltje Adema, dr.","Frisius Medisch Centrum",{"name":39,"affiliation":40,"role":34},"Femke Waanders, dr.","Isala Zwolle",{"name":42,"affiliation":5,"role":43},"Martin de Borst, prof. dr.","STUDY_CHAIR",[45,49],{"name":42,"role":46,"phone":47,"phoneExt":26,"email":48},"CONTACT","+31503616161","m.h.de.borst@umcg.nl",{"name":50,"role":46,"phone":47,"phoneExt":26,"email":51},"Caspar van Lieshout, MD","c.j.van.lieshout@umcg.nl",[53],{"facility":5,"status":54,"city":55,"state":26,"zip":26,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Groningen","Netherlands","NL",{"type":59,"coordinates":60},"Point",[61,62],6.56667,53.21917,{"lat":62,"lon":61},[65],{"name":42,"role":46,"phone":26,"phoneExt":26,"email":26},{"type":67,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[69,71,72,74,77,79],{"name":70,"class":6},"Amsterdam University Medical Center",{"name":37,"class":6},{"name":73,"class":6},"Isala",{"name":75,"class":76},"Vifor Pharma, Inc.","INDUSTRY",{"name":78,"class":6},"Dutch Kidney Foundation",{"name":80,"class":6},"Health Holland","100535835","phase-4-potassium-correction-for-raas-optimization-in-chronic-kidney-disease-100535835",false,"NCT06256991","Potassium Correction for RAAS Optimization in Chronic Kidney Disease","Potassium Correction for Renin-angiotensin-aldosterone System Optimization in Chronic Kidney Disease","PROMISE","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* CKD stage 3b-4 (eGFR 15-44 mL\u002Fmin\u002F1.73 m2)\n* Albumin-creatinine ratio \\>3 mg\u002Fmmol, or proteinuria \\>0.05g\u002F24u, or protein-creatinine ratio \\> 5mg\u002Fmmol\n* Systolic blood pressure \\>130 mmHg or use of one or more antihypertensive drugs;\n* Serum K+ 4.0-5.0 mmol\u002FL;\n* On sub-maximal dose ACEi\u002FARB\n\nExclusion Criteria:\n\n* prior ACEi\u002FARB dose reduction due to a drop in eGFR by \\>25% in the last year;\n* history of severe hyperkalaemia (\\>6.0 mmol\u002FL) in the last year;\n* pregnancy or breastfeeding\n* life expectancy \\\u003C12 months\n* the use of lithium, potassium-sparing diuretics, potassium supplements, trimethoprim or NSAIDS\n* kidney transplant recipients, or diagnosis of autosomal dominant polycystic kidney disease or other non-glomerular kidney disease","ALL","18 Years",{"count":92,"type":93},44,"ESTIMATED","INTERVENTIONAL",[96],"PHASE4","The goal of this placebo-controlled, double-blinded cross-over trial is to test whether patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with chronic kidney disease stage 3b\u002F4.\n\nThe main questions it aims to answer are:\n\n* Does patiromer allow uptitration of irbesartan, resulting in a significant reduction in albuminuria and blood pressure?\n* Does patiromer allow uptitration of irbesartan, resulting in a significant reduction in blood pressure?\n\nThe trial contains the following interventions:\n\n* Participants will be switched from their ACEi\u002FARB to a standardised dose of irbesartan (150 mg\u002Fd).\n* During two 12-week study periods, participants will receive either patiromer 8.4 g\u002Fd or placebo. The order of study periods is randomized.\n* At the start of each study period irbesartan will be up-titrated to 300 mg\u002Fd.\n* After 1 and 6 weeks, at both periods, plasma potassium will be measured and the irbesartan dose will be reduced to 150 mg\u002Fd in case plasma potassium exceeds 5.0 mmol\u002FL.\n* At 12 weeks from the start of the study period, the endpoints will be assessed.\n* Between the two study periods, there is a 6-week washout. Irbesartan dose during the wash-out period will be 150mg\u002Fd. After washout, participants will switch from the patiromer arm to the placebo arm or vice versa.",[99,100,101],"Chronic Kidney Diseases","Hyperkalemia","Hypertension","2025-12-12",{"date":104,"type":105},"2025-12-19","ACTUAL",{"date":107,"type":105},"2024-04-01",{"date":109,"type":93},"2027-12",{"name":5,"class":6},1]